Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $13.75.

Several brokerages have weighed in on VYGR. Weiss Ratings reiterated a “sell (d)” rating on shares of Voyager Therapeutics in a report on Wednesday, October 8th. HC Wainwright lowered their price objective on Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, November 12th. Wedbush reiterated an “outperform” rating and issued a $8.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, November 11th. Finally, Wall Street Zen upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th.

Voyager Therapeutics Price Performance

Voyager Therapeutics stock opened at $3.67 on Wednesday. The stock has a market capitalization of $204.05 million, a P/E ratio of -1.70 and a beta of 1.28. Voyager Therapeutics has a 12-month low of $2.64 and a 12-month high of $5.96. The firm’s 50-day moving average is $4.09 and its two-hundred day moving average is $4.03.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.06. The business had revenue of $11.15 million during the quarter, compared to analyst estimates of $7.86 million. Voyager Therapeutics had a negative net margin of 404.85% and a negative return on equity of 48.94%. As a group, analysts forecast that Voyager Therapeutics will post -0.91 EPS for the current year.

Institutional Investors Weigh In On Voyager Therapeutics

Several hedge funds have recently modified their holdings of the stock. Bank of Montreal Can purchased a new stake in Voyager Therapeutics in the second quarter valued at approximately $36,000. Wexford Capital LP purchased a new position in Voyager Therapeutics during the third quarter worth approximately $42,000. R Squared Ltd acquired a new position in shares of Voyager Therapeutics in the 2nd quarter valued at $48,000. Los Angeles Capital Management LLC purchased a new stake in shares of Voyager Therapeutics during the 2nd quarter valued at $50,000. Finally, Coldstream Capital Management Inc. purchased a new stake in shares of Voyager Therapeutics during the 3rd quarter valued at $55,000. 48.03% of the stock is owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.